BDBM160933 US20240208984, Compound VZMC002::US9107954, 2

SMILES CC(C)c1nnc(C)n1C1CC2CCC(C1)N2CC[C@H](NC(=O)C1CCC(F)(F)CC1)c1cccc(NC(=O)COCC(=O)NCCCCCCCNC(=O)COCC(=O)N[C@@H]2CC[C@@]3(O)[C@H]4Cc5ccc(O)c6O[C@@H]2[C@]3(CCN4CC2CC2)c56)c1

InChI Key

Data  2 KI  1 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 3 hits for monomerid = 160933   

TargetMu-type opioid receptor(Human)
Virginia Commonwealth University

US Patent
LigandPNGBDBM160933(US9107954, 2 | US20240208984, Compound VZMC002)
Affinity DataIC50: 37.8nMAssay Description:As Ca2+ flux is associated with the activation of the MOR, the functional activity of bivalent ligand 1, monovalent ligand 2, and naltrexone was then...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/11/2016
Entry Details
Go to US Patent

TargetMu-type opioid receptor(Human)
Virginia Commonwealth University

US Patent
LigandPNGBDBM160933(US9107954, 2 | US20240208984, Compound VZMC002)
Affinity DataKi:  9.20nMAssay Description:A bivalent ligand 1 (FIG. 14) that combines the pharmacophores of naltrexone (a MOR antagonist) and maraviroc (a CCR5 antagonist) into one molecule w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/11/2016
Entry Details
Go to US Patent

TargetProtein MOR1(Mouse-ear cress)
Virginia Commonwealth University

US Patent
LigandPNGBDBM160933(US9107954, 2 | US20240208984, Compound VZMC002)
Affinity DataKi:  9.20nMAssay Description:The competition binding assay was conducted using monoclonal mouse MOR expressed in Chinese hamster ovary (CHO) cell lines. In this assay, 30 μg...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/4/2024
Entry Details
Go to US Patent